The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.
about
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trialSafety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.Quantifying disease progression in amyotrophic lateral sclerosis.Commonalities and challenges in the development of clinical trial measures in neurology.Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis.The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onsetPredicting success: optimizing phase II ALS trials for the transition to phase III.Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Serum urate at trial entry and ALS progression in EMPOWER.Outcome measures in amyotrophic lateral sclerosis clinical trialsGlobal rank tests for multiple, possibly censored, outcomesPower and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.What are we measuring?Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.What can we learn from the edaravone development program for ALS?Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS.Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendationsTime to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational studyA post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS
P2860
Q26823418-629AE778-FA90-4FB2-A91F-282499AD4A30Q33569474-EBC9581F-658D-4BDA-8BEC-BFD53FF9E549Q34251334-574C28AE-58E9-4758-8FE8-9C8D10D51C33Q34436090-E44E1459-FDA0-465C-AAB7-86DA3B8CE6D5Q35008605-F8920C92-EDB1-4D21-903E-938625F5A9F6Q35064956-61A2AF71-5745-4DC9-9506-CE49C6517067Q35686186-566B7EF9-5A75-48DB-BF33-25D25E08123FQ37107393-D49376CB-2BA5-41CA-9F2A-676BDB00CAB2Q38192690-C93DC9A9-EDD5-4AA4-89AB-48FD34F0A246Q38223292-BEFC4582-0190-40B0-ACF2-50EC00176895Q38383918-A60E39AC-EAC3-4FDE-A3DD-984806C9341EQ38847200-8794B7DC-B2A8-4920-A763-B07C60DBC939Q40563709-A9E9F112-49BB-48AE-B09A-7B141F9D40EFQ41837997-75FE0FFF-22C5-426D-94A0-8129F0D254CEQ41943653-C7B47753-77C9-4566-8C5C-75E0443FC0D8Q42266334-3F527A1B-79BD-402A-8C67-25C890CE0C26Q42687960-46ABB4B7-1811-4CC3-AE99-3ECA5AFB6CEDQ44346848-7E2BE1CB-8171-4276-9B0F-A139058049C9Q47180993-A86B589C-DFF1-4B7B-AE34-39127B1B12B5Q47648367-3E1FD1F3-CC1C-4FCB-BBDE-BFD4AE29C5B0Q48033706-50C10466-1D4F-4618-AC3D-275B447C7BE1Q50222481-77BAF67D-E060-41C5-93A5-E5112870C5EEQ51066498-BE764506-F5A5-443D-99E5-49778B100319Q51733178-00B556DF-BCB2-42C9-BD2D-2B0F21E0C79BQ51741753-DD649513-7263-417A-863E-3D8C73238581Q55245121-20575DDB-EA1A-4E9E-B8F8-8A9189FFB4A6Q57167257-1A760429-ED1D-4C42-A4A5-1B5E42C4BBA5Q58005566-89E5A96A-3C2E-4A78-9D2F-3B7C6BC0212AQ58271878-F6DBE7B8-5A92-459A-9D70-F999920513A3
P2860
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The Combined Assessment of Fun ...... point for ALS clinical trials.
@en
type
label
The Combined Assessment of Fun ...... point for ALS clinical trials.
@en
prefLabel
The Combined Assessment of Fun ...... point for ALS clinical trials.
@en
P2093
P2860
P1476
The Combined Assessment of Fun ...... point for ALS clinical trials.
@en
P2093
Dan H Moore
Donald Archibald
Douglas A Kerr
Evan W Ingersoll
James D Berry
Robert Miller
Yingwen Dong
P2860
P304
P356
10.3109/21678421.2012.762930
P577
2013-01-17T00:00:00Z